Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) CEO David P. Schenkein unloaded 13,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $46.52, for a total value of $604,760.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on AGIO. Analysts at Citigroup Inc. initiated coverage on shares of Agios Pharmaceuticals in a research note on Tuesday. They set a “buy” rating and a $58.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday, June 16th. They now have a $60.00 price target on the stock, up previously from $55.00. Finally, analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $52.96.

Agios Pharmaceuticals (NASDAQ:AGIO) traded down 1.97% on Wednesday, hitting $44.72. 281,849 shares of the company’s stock traded hands. Agios Pharmaceuticals has a 52-week low of $15.77 and a 52-week high of $50.37. The stock has a 50-day moving average of $40.64 and a 200-day moving average of $36.16. The company’s market cap is $1.518 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.38) by $0.01. On average, analysts predict that Agios Pharmaceuticals will post $-1.47 earnings per share for the current fiscal year.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.